1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Germ Cell Tumors - Pipeline Review, H2 2015

Germ Cell Tumors - Pipeline Review, H2 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 88 pages

Germ Cell Tumors - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Germ Cell Tumors - Pipeline Review, H2 2015’, provides an overview of the Germ Cell Tumors’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Germ Cell Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Germ Cell Tumors and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Germ Cell Tumors
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Germ Cell Tumors and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Germ Cell Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Germ Cell Tumors pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Germ Cell Tumors
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Germ Cell Tumors pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Germ Cell Tumors - Pipeline Review, H2 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Germ Cell Tumors Overview 7
Therapeutics Development 8
Pipeline Products for Germ Cell Tumors - Overview 8
Pipeline Products for Germ Cell Tumors - Comparative Analysis 9
Germ Cell Tumors - Therapeutics under Development by Companies 10
Germ Cell Tumors - Therapeutics under Investigation by Universities/Institutes 11
Germ Cell Tumors - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Germ Cell Tumors - Products under Development by Companies 14
Germ Cell Tumors - Products under Investigation by Universities/Institutes 15
Germ Cell Tumors - Companies Involved in Therapeutics Development 16
AB Science SA 16
ArQule, Inc. 17
Astex Pharmaceuticals, Inc. 18
GlaxoSmithKline Plc 19
MediGene AG 20
Merck and Co., Inc. 21
Novartis AG 22
Philogen S.p.A. 23
Sanofi 24
Germ Cell Tumors - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
cabazitaxel - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Cell Therapy 1 for Oncology - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
G-207 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
guadecitabine - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
pembrolizumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
ribociclib - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Small Molecule to Antagonize KIT816 for Aggressive Mastocytosis, Seminoma and AML - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Small Molecules to Inhibit Tubulin for Oncology - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
Tetravil - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
tivantinib - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Germ Cell Tumors - Recent Pipeline Updates 65
Germ Cell Tumors - Dormant Projects 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 87
Disclaimer 88

List of Tables
Number of Products under Development for Germ Cell Tumors, H2 2015 8
Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Germ Cell Tumors - Pipeline by AB Science SA, H2 2015 16
Germ Cell Tumors - Pipeline by ArQule, Inc., H2 2015 17
Germ Cell Tumors - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 18
Germ Cell Tumors - Pipeline by GlaxoSmithKline Plc, H2 2015 19
Germ Cell Tumors - Pipeline by MediGene AG, H2 2015 20
Germ Cell Tumors - Pipeline by Merck and Co., Inc., H2 2015 21
Germ Cell Tumors - Pipeline by Novartis AG, H2 2015 22
Germ Cell Tumors - Pipeline by Philogen S.p.A., H2 2015 23
Germ Cell Tumors - Pipeline by Sanofi, H2 2015 24
Assessment by Monotherapy Products, H2 2015 25
Assessment by Combination Products, H2 2015 26
Number of Products by Stage and Target, H2 2015 28
Number of Products by Stage and Mechanism of Action, H2 2015 30
Number of Products by Stage and Route of Administration, H2 2015 32
Number of Products by Stage and Molecule Type, H2 2015 34
Germ Cell Tumors Therapeutics - Recent Pipeline Updates, H2 2015 65
Germ Cell Tumors - Dormant Projects, H2 2015 86

List of Figures
Number of Products under Development for Germ Cell Tumors, H2 2015 8
Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Monotherapy Products, H2 2015 25
Number of Products by Top 10 Targets, H2 2015 27
Number of Products by Stage and Top 10 Targets, H2 2015 27
Number of Products by Top 10 Mechanism of Actions, H2 2015 29
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 29
Number of Products by Top 10 Routes of Administration, H2 2015 31
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 31
Number of Products by Top 10 Molecule Types, H2 2015 33
Number of Products by Stage and Top 10 Molecule Types, H2 2015 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.